A gene-editing therapy has reportedly freed the first trial participant from symptoms of sickle cell disease. Other treatments, including Casgevy, Mitapivat, and Risto-cel, are also being tested for their effectiveness in managing the disease, with some showing promise in preventing sickle cell crises and easing symptoms. The field appears to be active, with multiple therapies and methods, including non-gene editing approaches, being explored to address sickle cell disease.